Stockscreener 앱 받기
50.92
1.37%
0.725
전일 마감가:
$50.20
열려 있는:
$50.78
하루 거래량:
412.76K
Relative Volume:
0.12
시가총액:
$22.57B
수익:
$2.38B
순이익/손실:
$1.32B
주가수익비율:
28.60
EPS:
1.7806
순현금흐름:
$897.24M
1주 성능:
+2.86%
1개월 성능:
+6.23%
6개월 성능:
+31.97%
1년 성능:
+53.73%
1일 변동 폭
$50.61
$51.17
1주일 범위
$49.11
$51.65
52주 변동 폭
$32.15
$51.65
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
50.91 | 22.25B | 2.38B | 1.32B | 897.24M | 1.7806 |
VRTX
Vertex Pharmaceuticals Inc
|
431.40 | 107.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
715.72 | 74.34B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
791.65 | 48.96B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.75 | 39.51B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
317.64 | 32.89B | 5.36B | 287.73M | 924.18M | 2.5229 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 업그레이드 | UBS | Neutral → Buy |
| 2025-09-30 | 개시 | Goldman | Buy |
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Royalty Pharma raises 2026 portfolio receipts guidance to $3.325B-$3.45B as it scales R&D co-funding - MSN
Royalty Pharma to Present at Upcoming Investor Conferences - Moomoo
Citigroup Raises Royalty Pharma (NASDAQ:RPRX) Price Target to $66.00 - MarketBeat
Royalty Pharma schedules two May healthcare conference webcasts - Stock Titan
JPMorgan Chase & Co. Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price - MarketBeat
Denali Therapeutics (NASDAQ: DNLI) adds cash on AVLAYAH deal despite Q1 loss - Stock Titan
Theravance Biopharma (NASDAQ: TBPH) slashes R&D after ampreloxetine trial miss - Stock Titan
Vanguard Group Inc. Cuts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Q1 2026 Earnings Call Transcript - Insider Monkey
Royalty Pharma Q1 2026 slides: double-digit growth, guidance raised By Investing.com - Investing.com Australia
Improved Growth Outlook Prompts Fair Value Estimate Increase for Narrow-Moat Royalty Pharma - Morningstar
Royalty Pharma’s Earnings Call Signals Confident Growth - TipRanks
Royalty Pharma Q1 Earnings Call Highlights - MarketBeat
MSN Money - MSN
Royalty Pharma plc Q1 2026 Financial Results: Earnings, Revenue, and Risk Factors from Latest 10-Q Filing - Minichart
Royalty Pharma Q1 2026 earnings preview - MSN
Royalty Pharma plc Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Royalty Pharma Q1 2026 shows robust growth By Investing.com - Investing.com India
Royalty Pharma Reports 10% Growth in Portfolio Receipts for Q1 2026 Driven by Strong Product Performance - Minichart
RPRX vs. AMGN: Which Stock Is the Better Value Option? - Yahoo! Finance Canada
Royalty Pharma Q1 2026 slides: double-digit growth, guidance raised - Investing.com
Royalty Pharma plc Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Royalty Pharma (RPRX) Valuation Check As Q1 Earnings Expectations Drive Strong Share Price Momentum - Sahm
Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Earnings call transcript: Royalty Pharma Q1 2026 shows robust growth - Investing.com
Royalty Pharma PLC (RPRX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Royalty Pharma (RPRX) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on January 10, 2025. - marketscreener.com
Royalty Pharma (NASDAQ: RPRX) grows Q1 2026 profit and cash flow - Stock Titan
Royalty Pharma plc 2026 Q1ResultsEarnings Call Presentation (NASDAQ:RPRX) 2026-05-06 - Seeking Alpha
Earnings Flash (RPRX) Royalty Pharma plc Reports Q1 Revenue $631.0M - marketscreener.com
Royalty Pharma : Q1 2026 Financial Results Presentation - marketscreener.com
Royalty Pharma (Nasdaq: RPRX) posts strong Q1 2026 growth and raises full-year guidance - Stock Titan
Royalty Pharma PLC $RPRX Position Reduced by Swedbank AB - MarketBeat
Royalty Pharma reports first quarter 2026 results - The Manila Times
Royalty Pharma commits up to $1.25B to new deals, lifts 2026 outlook - Stock Titan
RPRX|Royalty Pharma PLC|Price:50.440|Chg%:0.24 - TradingKey
Royalty Pharma stock hits 52-week high at 50.49 USD By Investing.com - Investing.com Australia
Royalty Pharma earnings in focus as deal activity accelerates By Investing.com - Investing.com South Africa
Royalty Pharma to Announce Q1 Earnings on May 6 - Intellectia AI
Royalty Pharma (NASDAQ:RPRX) Hits New 52-Week HighStill a Buy? - MarketBeat
Royalty Pharma stock hits 52-week high at 50.49 USD - Investing.com
Royalty Pharma Plc Hits New 52-Week High of $50.47 - Markets Mojo
The Technical Signals Behind (RPRX) That Institutions Follow - Stock Traders Daily
Royalty Pharma PLC $RPRX Shares Bought by UBS Group AG - MarketBeat
Royalty Pharma plc (RPRX): Analyst Consensus Signals Potential Upside Amid Biotech Growth - DirectorsTalk Interviews
Hussman Strategic Advisors Inc. Buys New Stake in Royalty Pharma PLC $RPRX - MarketBeat
PFA Pension Forsikringsaktieselskab Acquires New Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Holdings Lifted by CM Management LLC - MarketBeat
Royalty Pharma’s Q2 2026 Dividend Raises a Deeper Question About Its Capital Allocation Strategy (RPRX) - Sahm
Pictet Asset Management Holding SA Sells 62,539 Shares of Royalty Pharma PLC $RPRX - MarketBeat
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.88%
0.57%
자본화:
|
볼륨(24시간):